Prepared by:
Johns Hopkins Evidence-based Practice Center
Sherita Golden, M.D., M.H.S.
L. Ebony Boulware, M.D., M.P.H.
Co-Principal Investigators
Gail Berkenblit, M.D., Ph.D.
Frederick L. Brancati, M.D., M.H.S.
Geetanjali Chander, M.D., M.P.H.
Spyridon Marinopoulos, M.D., M.B.A.
Michael Paasche-Orlow, M.D., M.P.H.
Neil Powe, M.D., M.P.H., M.B.A
Tejal Rami, M.P.H.
Investigators
File Name Description Software Version File Size ________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 2002 35KB 3 pages Contents: Title Page, Preface ________________________________________________________________________________________________ 02abstr.doc Microsoft Word® Document MS Word® 2002 23KB 2 pages Contents: Structured Abstract ________________________________________________________________________________________________ 03conts.doc Microsoft Word® Document MS Word® 2002 32KB 3 pages Contents: Table of Contents ________________________________________________________________________________________________ 04summ.doc Microsoft Word® Document MS Word® 2002 67KB 9 pages Contents: Summary ________________________________________________________________________________________________ 05chap1.doc Microsoft Word® Document MS Word® 2002 87KB 7 pages Contents: Chapter 1. Introduction: Background, Key Questions ________________________________________________________________________________________________ 06chap2.doc Microsoft Word® Document MS Word® 2002 45KB 6 pages Contents: Chapter 2. Methodology: Recruitment of Technical Experts and Peer Reviewers, Process of Systematic Review, Glycemic Control, Urine Albumin, Assessment of Study Quality, Calculation of Weighted Averages ________________________________________________________________________________________________ 07chap3.doc Microsoft Word® Document MS Word® 2002 449KB 46 pages Contents: Chapter 3. Results: Glycemic Control, Urine Albumin ________________________________________________________________________________________________ 08chap4.doc Microsoft Word® Document MS Word® 2002 37KB 5 pages Contents: Chapter 4. Conclusions and Limitations: Glycemic Control, Urine Albumin ________________________________________________________________________________________________ 09chap5.doc Microsoft Word® Document MS Word® 2002 29KB 2 pages Contents: Chapter 5. Future Research: Glycemic Control, Urine Albumin ________________________________________________________________________________________________ 10refs.doc Microsoft Word® Document MS Word® 2002 82KB 11 pages Contents: References ________________________________________________________________________________________________ 11etbl1.doc Microsoft Word® Document MS Word® 2002 295KB 17 pages Contents: Evidence Table 1. Study Population, Design, Location, Recruitment, Outcomes, Quality ________________________________________________________________________________________________ 12etbl2.doc Microsoft Word® Document MS Word® 2002 614KB 23 pages Contents: Evidence Table 2. Baseline Data for All Study Participants; Cohort Studies ________________________________________________________________________________________________ 13etbl3.doc Microsoft Word® Document MS Word® 2002 104KB 3 pages Contents: Evidence Table 3. Baseline Data for All Study Participants; Randomized Controlled Trials ________________________________________________________________________________________________ 14etbl4.doc Microsoft Word® Document MS Word® 2002 408KB 12 pages Contents: Evidence Table 4. Diagnosis of Diabetes; Cohort Studies ________________________________________________________________________________________________ 15etbl5.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 5. Diagnosis of Diabetes; Randomized Controlled Trials ________________________________________________________________________________________________ 16etbl6.doc Microsoft Word® Document MS Word® 2002 120KB 3 pages Contents: Evidence Table 6. Retinopathy: Cohort Studies: Incident Retinopathy, type 1 diabetes ________________________________________________________________________________________________ 17etbl7.doc Microsoft Word® Document MS Word® 2002 141KB 4 pages Contents: Evidence Table 7. Retinopathy: Cohort Studies: Incident Retinopathy, type 2 diabetes ________________________________________________________________________________________________ 18etbl8.doc Microsoft Word® Document MS Word® 2002 140KB 6 pages Contents: Evidence Table 8. Retinopathy: Cohort Studies: Incident Proliferate Retinopathy/ Macular Edema, type 1 diabetes ________________________________________________________________________________________________ 19etbl9.doc Microsoft Word® Document MS Word® 2002 111KB 4 pages Contents: Evidence Table 9. Retinopathy: Cohort Studies: Incident Proliferate Retinopathy/ Macular Edema, type 2 diabetes ________________________________________________________________________________________________ 20etbl10.doc Microsoft Word® Document MS Word® 2002 146KB 5 pages Contents: Evidence Table 10. Retinopathy: Cohort Studies: Progression of Retinopathy, type 1 diabetes ________________________________________________________________________________________________ 21etbl11.doc Microsoft Word® Document MS Word® 2002 93KB 3 pages Contents: Evidence Table 11. Retinopathy: Cohort Studies: Progression of Retinopathy, type 2 diabetes ________________________________________________________________________________________________ 22etbl12.doc Microsoft Word® Document MS Word® 2002 59KB 2 pages Contents: Evidence Table 12. Retinopathy: Cohort Studies: Blindness/ Visual Acuity, type 1 diabetes ________________________________________________________________________________________________ 23etbl13.doc Microsoft Word® Document MS Word® 2002 42KB 1 page Contents: Evidence Table 13. Retinopathy: Cohort Studies: Blindness / Visual Acuity, type 2 diabetes ________________________________________________________________________________________________ 24etbl14.doc Microsoft Word® Document MS Word® 2002 57KB 2 pages Contents: Evidence Table 14. Retinopathy: Cohort Studies: Cataract Extraction, type 2 diabetes ________________________________________________________________________________________________ 25etbl15.doc Microsoft Word® Document MS Word® 2002 42KB 1 page Contents: Evidence Table 15. Retinopathy: Randomized Controlled Trials: Incident Retinopathy, type 1 diabetes ________________________________________________________________________________________________ 26etbl16.doc Microsoft Word® Document MS Word® 2002 32KB 1 page Contents: Evidence Table 16. Retinopathy: Randomized Controlled Trials: Incident Retinopathy, type 2 diabetes ________________________________________________________________________________________________ 27etbl17.doc Microsoft Word® Document MS Word® 2002 32KB 1 page Contents: Evidence Table 17. Retinopathy: Randomized Controlled Trials: Incident Proliferative Retinopathy, type 1 diabetes ________________________________________________________________________________________________ 28etbl18.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 18. Retinopathy: Randomized Controlled Trials: Incident Proliferative Retinopathy, type 2 diabetes ________________________________________________________________________________________________ 29etbl19.doc Microsoft Word® Document MS Word® 2002 53KB 2 pages Contents: Evidence Table 19. Retinopathy: Randomized Controlled Trials: Progression of Retinopathy, type 1 diabetes ________________________________________________________________________________________________ 30etbl20.doc Microsoft Word® Document MS Word® 2002 49KB 2 pages Contents: Evidence Table 20. Retinopathy: Randomized Controlled Trials: Progression of Retinopathy, type 2 diabetes ________________________________________________________________________________________________ 31etbl21.doc Microsoft Word® Document MS Word® 2002 27KB 1 page Contents: Evidence Table 21. Retinopathy: Randomized Controlled Trials: Blindness / Visual Acuity, type 1 diabetes ________________________________________________________________________________________________ 32etbl22.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 22. Retinopathy: Randomized Controlled Trials: Blindness / Visual Acuity, type 2 diabetes ________________________________________________________________________________________________ 33etbl23.doc Microsoft Word® Document MS Word® 2002 27KB 1 page Contents: Evidence Table 23. Retinopathy: Randomized Controlled Trials: Cataract Extraction, type 2 diabetes ________________________________________________________________________________________________ 34etbl24.doc Microsoft Word® Document MS Word® 2002 170KB 7 pages Contents: Evidence Table 24. Nephropathy: Cohort Studies: Incidence/Progression of Microalbuminuria, type 1 diabetes ________________________________________________________________________________________________ 35etbl25.doc Microsoft Word® Document MS Word® 2002 98KB 3 pages Contents: Evidence Table 25. Nephropathy: Cohort Studies: Incidence/Progression of Microalbuminuria, type 2 diabetes ________________________________________________________________________________________________ 36etbl26.doc Microsoft Word® Document MS Word® 2002 75KB 3 pages Contents: Evidence Table 26. Nephropathy: Cohort Studies: Incidence/Progression of Macroalbuminuria, type 1 diabetes ________________________________________________________________________________________________ 37etbl27.doc Microsoft Word® Document MS Word® 2002 46KB 2 pages Contents: Evidence Table 27. Nephropathy: Cohort Studies Incidence/Progression of Macroalbuminuria (combined endpoint), type 2 diabetes ________________________________________________________________________________________________ 38etbl28.doc Microsoft Word® Document MS Word® 2002 27KB 1 page Contents: Evidence Table 28. Nephropathy: Cohort Studies: Progression of Nephropathy, type 1 diabetes ________________________________________________________________________________________________ 39etbl29.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 29. Nephropathy: Cohort Studies: Progression of Nephropathy, type 2 diabetes ________________________________________________________________________________________________ 40etbl30.doc Microsoft Word® Document MS Word® 2002 51KB 2 pages Contents: Evidence Table 30. Nephropathy: Cohort Studies: Change in GFR/ Creatinine Clearance, type 1 diabetes ________________________________________________________________________________________________ 41etbl31.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 31. Nephropathy: Cohort Studies: End-stage renal disease: Renal replacement therapy or transplant, type 1 diabetes ________________________________________________________________________________________________ 42etbl32.doc Microsoft Word® Document MS Word® 2002 26KB 1 page Contents: Evidence Table 32. Nephropathy: Cohort Studies: End-stage renal disease: Renal replacement therapy or transplant, type 2 diabetes ________________________________________________________________________________________________ 43etbl33.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 33. Nephropathy: Randomized Controlled Trials: Incidence/Progression of Microalbuminuria, type 1 diabetes ________________________________________________________________________________________________ 44etbl34.doc Microsoft Word® Document MS Word® 2002 46KB 2 pages Contents: Evidence Table 34. Nephropathy: Randomized Controlled Trials: Incidence/Progression of Microalbuminuria, type 2 diabetes ________________________________________________________________________________________________ 45etbl35.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 35. Nephropathy: Randomized Controlled Trials: Incidence/Progression of Macroalbuminuria, type 1 diabetes ________________________________________________________________________________________________ 46etbl36.doc Microsoft Word® Document MS Word® 2002 42KB 1 page Contents: Evidence Table 36. Nephropathy: Randomized Controlled Trials: Incidence/Progression of Macroalbuminuria, type 2 diabetes ________________________________________________________________________________________________ 47etbl37.doc Microsoft Word® Document MS Word® 2002 30KB 1 page Contents: Evidence Table 37. Nephropathy: Randomized Controlled Trials: Progression of Nephropathy, type 1 diabetes ________________________________________________________________________________________________ 48etbl38.doc Microsoft Word® Document MS Word® 2002 31KB 1 page Contents: Evidence Table 38. Nephropathy: Randomized Controlled Trials: Progression of Nephropathy, type 2 diabetes ________________________________________________________________________________________________ 49etbl39.doc Microsoft Word® Document MS Word® 2002 65KB 2 pages Contents: Evidence Table 39. Neuropathy: Cohort Study: Peripheral Neuropathy, type 1 diabetes ________________________________________________________________________________________________ 50etbl40.doc Microsoft Word® Document MS Word® 2002 39KB 2 pages Contents: Evidence Table 40. Neuropathy: Cohort Study: Peripheral Neuropathy, type 2 diabetes ________________________________________________________________________________________________ 51etbl41.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 41. Neuropathy: Cohort Study: Autonomic Neuropathy, type 1 diabetes ________________________________________________________________________________________________ 52etbl42.doc Microsoft Word® Document MS Word® 2002 56KB 2 pages Contents: Evidence Table 42. Neuropathy: Randomized Controlled Trials: Peripheral Neuropathy, type 1 diabetes ________________________________________________________________________________________________ 53etbl43.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 43. Neuropathy: Randomized Controlled Trials: Peripheral Neuropathy, type 2 diabetes ________________________________________________________________________________________________ 54etbl44.doc Microsoft Word® Document MS Word® 2002 27KB 1 page Contents: Evidence Table 44. Neuropathy: Randomized Controlled Trials: Autonomic Neuropathy, type 2 diabetes ________________________________________________________________________________________________ 55etbl45.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 45. Macrovascular: Cause Specific Cardiovascular Morbidity-Coronary Artery Disease: Cohort Studies: Angina, Non-fatal Myocardial Infarction, type 2 diabetes ________________________________________________________________________________________________ 56etbl46.doc Microsoft Word® Document MS Word® 2002 29KB 1 page Contents: Evidence Table 46. Macrovascular: Cause Specific Cardiovascular Morbidity-Cerebrovascular Disease: Cohort Studies: Non-fatal Stroke, type 2 diabetes ________________________________________________________________________________________________ 57etbl47.doc Microsoft Word® Document MS Word® 2002 84KB 3 pages Contents: Evidence Table 47. Macrovascular: Cause Specific Cardiovascular Morbidity-Peripheral Arterial Disease: Cohort Studies: Non-fatal Peripheral Arterial Disease, type 1 diabetes ________________________________________________________________________________________________ 58etbl48.doc Microsoft Word® Document MS Word® 2002 57KB 2 pages Contents: Evidence Table 48. Macrovascular: Cause Specific Cardiovascular Morbidity-Peripheral Arterial Disease: Cohort Studies: Non-fatal Peripheral Arterial Disease, type 2 diabetes ________________________________________________________________________________________________ 59etbl49.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 49. Macrovascular: Cause Specific Cardiovascular Morbidity-Congestive Heart Failure: Cohort Studies: Congestive Heart Failure, type 2 diabetes ________________________________________________________________________________________________ 60etbl50.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 50. Macrovascular: Cause Specific Cardiovascular Morbidity-Carotid IMT: Cohort Studies: Carotid IMT, type 1 diabetes ________________________________________________________________________________________________ 61etbl51.doc Microsoft Word® Document MS Word® 2002 26KB 1 page Contents: Evidence Table 51. Macrovascular: Cause Specific Cardiovascular Morbidity-Carotid IMT: Cohort Studies: Carotid IMT, type 2 diabetes ________________________________________________________________________________________________ 62etbl52.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 52. Macrovascular: Cause Specific Cardiovascular Mortality-Coronary Artery Disease: Cohort Studies: Fatal Myocardial Infarction, type 1 diabetes ________________________________________________________________________________________________ 63etbl53.doc Microsoft Word® Document MS Word® 2002 48KB 2 pages Contents: Evidence Table 53. Macrovascular: Cause Specific Cardiovascular Mortality-Coronary Artery Disease: Cohort Studies: Fatal Myocardial Infarction, type 2 diabetes ________________________________________________________________________________________________ 64etbl54.doc Microsoft Word® Document MS Word® 2002 29KB 1 page Contents: Evidence Table 54. Macrovascular: Cause Specific Cardiovascular Mortality- Cerebrovascular Disease: Cohort Studies: Fatal Stroke, type 2 diabetes ________________________________________________________________________________________________ 65etbl55.doc Microsoft Word® Document MS Word® 2002 43KB 1 page Contents: Evidence Table 55. Macrovascular: Composite Cardiovascular Mortality-Fatal Myocardial Infarction or Stroke: Cohort Studies: Fatal Myocardial Infarction or Stroke, type 2 diabetes ________________________________________________________________________________________________ 66etbl56.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 56. Macrovascular: Composite CVD Morbidity and Mortality- Cardiovascular Disease: Cohort Studies: Fatal and Non-fatal Myocardial Infarction, type 1 diabetes ________________________________________________________________________________________________ 67etbl57.doc Microsoft Word® Document MS Word® 2002 54KB 2 pages Contents: Evidence Table 57. Macrovascular: Composite CVD Mortality-Cardiovascular Disease: Cohort Studies: Fatal and Non-fatal Myocardial Infarction, type 2 diabetes ________________________________________________________________________________________________ 68etbl58.doc Microsoft Word® Document MS Word® 2002 26KB 1 page Contents: Evidence Table 58. Macrovascular: Composite CVD Morbidity and Mortality- Cerebrovascular Disease: Cohort Studies: Fatal and Non-fatal Stroke, type 1 diabetes ________________________________________________________________________________________________ 69etbl59.doc Microsoft Word® Document MS Word® 2002 57KB 2 pages Contents: Evidence Table 59. Macrovascular: Composite CVD Morbidity and Mortality- Cerebrovascular Disease: Cohort Studies: Fatal and Non-fatal Stroke, type 2 diabetes ________________________________________________________________________________________________ 70etbl60.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 60. Macrovascular: Composite CVD Morbidity and Mortality- Cardiovascular Disease: Randomized Controlled Trial: Fatal and Non-fatal Myocardial Infarction, type 2 diabetes ________________________________________________________________________________________________ 71etbl61.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 61. Macrovascular: Composite CVD Morbidity and Mortality- Cerebrovascular Disease: Randomized Controlled Trial: Fatal and Non-Fatal Stroke, type 2 diabetes ________________________________________________________________________________________________ 72etbl62.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 62. Macrovascular: Composite CVD Morbidity and Mortality- Peripheral Arterial Disease: Randomized Controlled Trial: Fatal and Non-fatal peripheral vascular disease, type 2 diabetes ________________________________________________________________________________________________ 73etbl63.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 63. Macrovascular Cause Specific Cardiovascular Morbidity-Congestive Heart Failure: Randomized Controlled Trial: Congestive Heart Failure, type 2 diabetes ________________________________________________________________________________________________ 74etbl64.doc Microsoft Word® Document MS Word® 2002 37KB 2 pages Contents: Evidence Table 64. Studies Examining Threshold Effect Between Glycosylated Hemoglobin and Retinopathy ________________________________________________________________________________________________ 75etbl65.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 65. Studies Examining Threshold Effect Between Glycosylated Hemoglobin and Nephropathy ________________________________________________________________________________________________ 76etbl66.doc Microsoft Word® Document MS Word® 2002 27KB 1 page Contents: Evidence Table 66. Studies Examining Threshold Effect Between Glycosylated Hemoglobin and Neuropathy ________________________________________________________________________________________________ 77etbl67.doc Microsoft Word® Document MS Word® 2002 25KB 1 page Contents: Evidence Table 67. Studies Examining Threshold Effect Between Glycosylated Hemoglobin and Macrovascular Complications ________________________________________________________________________________________________ 78etbl68.doc Microsoft Word® Document MS Word® 2002 117KB 5 pages Contents: Evidence Table 68. Study Population, Design, Location, Recruitment, Outcomes, Quality ________________________________________________________________________________________________ 79etbl69.doc Microsoft Word® Document MS Word® 2002 117KB 5 pages Contents: Evidence Table 69. Baseline Data for All Study Participants; Cohort Studies ________________________________________________________________________________________________ 80etbl70.doc Microsoft Word® Document MS Word® 2002 55KB 2 pages Contents: Evidence Table 70. Baseline Data for All Study Participants; Randomized Controlled Trials ________________________________________________________________________________________________ 81etbl71.doc Microsoft Word® Document MS Word® 2002 114KB 4 pages Contents: Evidence Table 71. Diagnosis of Diabetes; Cohort Studies ________________________________________________________________________________________________ 82etbl72.doc Microsoft Word® Document MS Word® 2002 31KB 1 page Contents: Evidence Table 72. Diagnosis of Diabetes; Randomized Controlled Trials ________________________________________________________________________________________________ 83etbl73.doc Microsoft Word® Document MS Word® 2002 29KB 1 page Contents: Evidence Table 73. Renal Outcomes; Cohort Studies: Change in GFR at Study Follow Up ________________________________________________________________________________________________ 84etbl74.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 74. Renal Outcomes; Cohort Studies: Rate of Change in GFR ________________________________________________________________________________________________ 85etbl75.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 75. Renal Outcomes; Cohort Studies: Rate of change of 1/serum creatinine ________________________________________________________________________________________________ 86etbl76.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 76. Renal Outcomes; Cohort Studies: Rate of change in creatinine clearance ________________________________________________________________________________________________ 87etbl77.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 77. Renal Outcomes; Cohort Studies: Incidence of ESRD, need for renal replacement therapy, or kidney transplantation ________________________________________________________________________________________________ 88etbl78.doc Microsoft Word® Document MS Word® 2002 27KB 1 page Contents: Evidence Table 78. Renal Outcomes; Randomized Controlled Trials: Change in GFR at Study Follow Up ________________________________________________________________________________________________ 89etbl79.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 79. Renal Outcomes; Randomized Controlled Trials: Rate of Change in GFR ________________________________________________________________________________________________ 90etbl80.doc Microsoft Word® Document MS Word® 2002 27KB 1 page Contents: Evidence Table 80. Renal Outcomes; Randomized Controlled Trials: Change in Creatinine Clearance at Study Follow up ________________________________________________________________________________________________ 91etbl81.doc Microsoft Word® Document MS Word® 2002 27KB 1 page Contents: Evidence Table 81. Renal Outcomes; Randomized Controlled Trials: Rate of Change in Creatinine Clearance ________________________________________________________________________________________________ 92etbl82.doc Microsoft Word® Document MS Word® 2002 48KB 1 page Contents: Evidence Table 82. All Cause Mortality; Cohort Studies: type 1 diabetes ________________________________________________________________________________________________ 93etbl83.doc Microsoft Word® Document MS Word® 2002 151KB 5 pages Contents: Evidence Table 83. All Cause Mortality; Cohort Studies: type 2 diabetes ________________________________________________________________________________________________ 94etbl84.doc Microsoft Word® Document MS Word® 2002 48KB 1 page Contents: Evidence Table 84. All Cause Mortality; Cohort Studies: type 1 and 2 diabetes or Diabetes Type Not Specified (NOS) ________________________________________________________________________________________________ 95etbl85.doc Microsoft Word® Document MS Word® 2002 45KB 1 page Contents: Evidence Table 85. All Cause Mortality; Clinical Trials Analyzed as Cohort Studies: type 1 and 2 diabetes or Diabetes Type Not Specified (NOS) ________________________________________________________________________________________________ 96etbl86.doc Microsoft Word® Document MS Word® 2002 26KB 1 page Contents: Evidence Table 86. All Cause Mortality; Randomized Controlled Trials: type 2 diabetes ________________________________________________________________________________________________ 97etbl87.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 87. Composite CVD Mortality; Cohort Studies: type 1 diabetes ________________________________________________________________________________________________ 98etbl88.doc Microsoft Word® Document MS Word® 2002 109KB 4 pages Contents: Evidence Table 88. Composite CVD Mortality; Cohort Studies: type 2 diabetes ________________________________________________________________________________________________ 99etbl89.doc Microsoft Word® Document MS Word® 2002 26KB 1 page Contents: Evidence Table 89. Composite CVD Mortality; Randomized Controlled Trials: type 2 diabetes ________________________________________________________________________________________________ 100etb90.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 90. Cause Specific CVD Mortality; Cohort Studies: Myocardial Infarction type 1 diabetes ________________________________________________________________________________________________ 101etb91.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 91. Cause Specific CVD Mortality; Cohort Studies: Myocardial Infarction type 2 diabetes ________________________________________________________________________________________________ 102etb92.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 92. Cause Specific CVD Mortality; Cohort Studies: Cerebrovascular Accident, type 1 diabetes ________________________________________________________________________________________________ 103etb93.doc Microsoft Word® Document MS Word® 2002 28KB 1 page Contents: Evidence Table 93. Cause Specific CVD Mortality; Cohort Studies: Cerebrovascular Accident, type 2 diabetes ________________________________________________________________________________________________ 104etb94.doc Microsoft Word® Document MS Word® 2002 42KB 2 pages Contents: Evidence Table 94. CVD Morbidity; Cohort Studies, type 1 diabetes ________________________________________________________________________________________________ 105etb95.doc Microsoft Word® Document MS Word® 2002 47KB 2 pages Contents: Evidence Table 95. CVD Morbidity; Cohort Studies, type 2 diabetes ________________________________________________________________________________________________ 106etb96.doc Microsoft Word® Document MS Word® 2002 48KB 1 page Contents: Evidence Table 96. CVD Morbidity; Clinical Trials Analyzed as Cohort Studies, type 1 and 2 diabetes ________________________________________________________________________________________________ 107etb97.doc Microsoft Word® Document MS Word® 2002 29KB 1 page Contents: Evidence Table 97. CVD Morbidity; Randomized Controlled Trials, type 2 diabetes ________________________________________________________________________________________________ 108etb98.doc Microsoft Word® Document MS Word® 2002 59KB 3 pages Contents: Evidence Table 98. CVD Morbidity and Mortality; Cohort Studies, type 2 diabetes ________________________________________________________________________________________________ 109etb99.doc Microsoft Word® Document MS Word® 2002 46KB 1 page Contents: Evidence Table 99. CVD Morbidity and Mortality; RCT Analyzed as Cohort Study, type 1 and 2 diabetes ________________________________________________________________________________________________ 110acros.doc Microsoft Word® Document MS Word® 2002 43KB 1 page Contents: Acronyms and Abbreviations ________________________________________________________________________________________________ 111gbib.doc Microsoft Word® Document MS Word® 2002 128KB 19 pages Contents: Glycohemoglobin Bibliography ________________________________________________________________________________________________ 112ubib.doc Microsoft Word® Document MS Word® 2002 76KB 9 pages Contents: Urine Albumin Bibliography ________________________________________________________________________________________________ 113aplst.doc Microsoft Word® Document MS Word® 2002 22KB 2 pages Contents: List of Appendixes ________________________________________________________________________________________________ 114appa.doc Microsoft Word® Document MS Word® 2002 24KB 2 pages Contents: Appendix A. Acknowledgments ________________________________________________________________________________________________ 115appb.doc Microsoft Word® Document MS Word® 2002 67KB 4 pages Contents: Appendix B. Study Questions: Refinement by Experts ________________________________________________________________________________________________ 116appc.doc Microsoft Word® Document MS Word® 2002 74KB 3 pages Contents: Appendix C. Glycohemoglobin (GHb) Testing ________________________________________________________________________________________________ 117appd.doc Microsoft Word® Document MS Word® 2002 23KB 2 pages Contents: Appendix D. EDTRS Criteria ________________________________________________________________________________________________ 118appe.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Appendix E. Glycohemoglobin Abstract Review Form ________________________________________________________________________________________________ 119appf1.doc Microsoft Word® Document MS Word® 2002 1.5MB 45 pages Contents: Appendix F. Glycohemoglobin and Diabetic Complications: Data Abstraction Tool ________________________________________________________________________________________________ 120appf2.doc Microsoft Word® Document MS Word® 2002 1.0MB 25 pages Contents: Appendix F. Glycohemoglobin and diabetic complications: PART II--Results ________________________________________________________________________________________________ 121appg.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Appendix G. Microalbuminuria Abstract Review Form ________________________________________________________________________________________________ 122apph1.doc Microsoft Word® Document MS Word® 2002 1.4MB 42 pages Contents: Appendix H. Microalbuminuria and Diabetic Complications: Data Abstraction Tool ________________________________________________________________________________________________ 123apph2.doc Microsoft Word® Document MS Word® 2002 848KB 21 pages Contents: Microalbuminuria and diabetic complications: PART II--Results ________________________________________________________________________________________________ 124appi.doc Microsoft Word® Document MS Word® 2002 25KB 1 page Contents: Appendix I. Research Team ________________________________________________________________________________________________
AHRQ Publication No. 04-E001
Current as of October 2003
Internet Citation:
Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus. File Inventory, Evidence Report/Technology Assessment Number 84. AHRQ Publication No. 04-E001, October 2003. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/glycainv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services